Search company, investor...
Sofie Biosciences company logo

Sofie Biosciences

sofie.com

Founded Year

2008

Stage

Loan | Alive

Total Raised

$16.65M

Last Raised

$3.5M | 3 yrs ago

About Sofie Biosciences

Sofie Biosciences develops and manufactures molecular imaging systems for oncology and immunology research. The company produces imaging systems, probes, and radiochemistry platforms for research laboratories.

Headquarters Location

6162 Bristol Parkway

Culver City, California, 90230,

United States

310-242-6794

Missing: Sofie Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sofie Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sofie Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sofie Biosciences is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health IT

7,901 items

Sofie Biosciences Patents

Sofie Biosciences has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/7/2017

3/17/2020

Chromatography, Fluid dynamics, Chemical synthesis, Chemical processes, Chemical reactions

Grant

Application Date

9/7/2017

Grant Date

3/17/2020

Title

Related Topics

Chromatography, Fluid dynamics, Chemical synthesis, Chemical processes, Chemical reactions

Status

Grant

Latest Sofie Biosciences News

08:00 ET IND granted for FAP targeting therapeutic in SOFIE partnership

Jan 17, 2023

News provided by Share this article Share this article DULLES, Va., Jan. 17, 2023 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, will be supporting, through companion diagnostic [68Ga]FAPI-46 PET, Yantai LNC Biotechnology's recently FDA accepted clinical study. On Jan 6th, 2023 Yantai LNC Biotechnology received FDA clearance to proceed with a Phase 1 clinical study of 177Lu-LNC1004 injection, targeting fibroblast activation protein (FAP). The study accepted as part of the FDA IND review is a Phase I, open label study of the safety and dosimetry of a 4-dose regimen of escalating doses of 177Lu-LNC1004 injection in adult patients with advanced FAP-positive solid tumors. As the companion diagnostic agent of 177Lu-LNC1004 Injection, [68Ga]FAPI-46 PET will be used to screen subjects and assess therapeutic effect. Yantai obtained access to [68Ga]FAPI-46 through a letter of cross reference to SOFIE Biosciences' IND along with corresponding precursor and reference standard for use. Prof. Xiaoyuan (Shawn) Chen, co-founder of Yantai LNC Biotechnology and editor-in-chief of the journal Theranostics, stated, "we appreciate the opportunity to work closely with SOFIE in pushing the long-acting FAPI formula 177Lu-LNC1004 forward. Applying Evans blue derivatives to modify pharmacokinetics and pharmacodynamics is a platform technology Yantai LNC Biotechnology has successfully implemented to multiple radioligands such as FAP inhibitors." Sherly Mosessian, Ph.D., SOFIE's Chief Scientific Officer, added, "as license holders of FAPI family of compounds for diagnostic and companion diagnostic use, we are excited to support this very promising study by having [68Ga]FAPI-46 serve as a companion diagnostic tool for patient selection and treatment monitoring with 177Lu-LNC1004. This highlights the power of theranostics in utilizing the same target, FAP, for imaging and treatment interventions." The study is expected to enroll up to 24 subjects in advanced solid tumors that show high level of FAP expression detected by [68Ga]FAPI-46 and will establish the recommended expansion phase dose with 177Lu-LNC1004. Site feasibility and selection is complete and the study is expected to launch in Singapore Q2 2023. About Yantai LNC Biotechnology Yantai LNC Biotechnology Singapore Pte. Ltd. is a wholly owned subsidiary of Yantai Dongcheng Pharmaceutical Group. As the unique innovative nuclear medicine development platform in Dongcheng Group, Yantai LNC Biotech is committed to radionuclide diagnosis and therapy innovation. For more information, contact  [email protected] . About 177Lu-LNC1004 177Lu-LNC1004 is a fibroblast activation protein inhibitor (FAPI) modified with Evans blue (EB) and a metal chelator (DOTA), radiolabeled with beta-emitting radionuclide lutetium Lu-177. As a first-in-class drug the FAP-targeting probe will be used to treat adult patients with advanced FAP-positive solid tumors. About FAPI Fibroblast Activation Protein (FAP)  is highly expressed in cancer associated fibroblasts (CAF) across several tumor entities. Developed by the team at the Heidelberg University Hospital (UKHD), quinoline-based PET tracers that act as FAP inhibitors (FAPI) have shown encouraging results in pre-clinical and clinical studies. SOFIE has licensed the rights for diagnostic and companion diagnostic use of FAPI family of compounds from Heidelberg University. [68Ga]FAPI-46 is the lead gallium-68 and [18F]FAPI-74 is the lead fluorine-18 radiolabeled PET tracer of FAPI family of compounds. They have demonstrated favorable dosimetry, avidity, safety and biodistribution profile amenable for detection of FAP-expressing cells in patients with various cancers. Both products have active INDs for Phase 2 studies in cancers of the digestive system. About SOFIE SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals. For more information, contact   [email protected] . SOURCE SOFIE

Sofie Biosciences Frequently Asked Questions (FAQ)

  • When was Sofie Biosciences founded?

    Sofie Biosciences was founded in 2008.

  • Where is Sofie Biosciences's headquarters?

    Sofie Biosciences's headquarters is located at 6162 Bristol Parkway, Culver City.

  • What is Sofie Biosciences's latest funding round?

    Sofie Biosciences's latest funding round is Loan.

  • How much did Sofie Biosciences raise?

    Sofie Biosciences raised a total of $16.65M.

  • Who are the investors of Sofie Biosciences?

    Investors of Sofie Biosciences include Paycheck Protection Program, Artiman Ventures, National Cancer Institute, Cycad Group, Tata Group and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.